Clin2
NCT06819293Possibly a fitRecruiting

IB-T101 injection for advanced kidney cancer

Advanced Clear Renal Cell CarcinomaAdult

Part of Cancer, Kidney & urinary clinical trials.

This trial tests an experimental injection called IB-T101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. It aims to see if the treatment is safe and possibly effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have advanced clear cell renal cell carcinoma and are willing to try an experimental treatment.
  • You are able to care for yourself (ECOG score 0 or 1).
  • Your doctor expects you to live at least 3 more months.
  • You do not have certain serious brain or nervous system conditions.
  • You have not had a heart attack or unstable chest pain in the last 6 months.
  • You do not have a serious immune system problem or HIV.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06342336Recruiting· Phase 1
HS-IT101 injection for advanced solid tumors

This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.

Beijing, Beijing Municipality
NCT07770802Not yet recruiting· Phase 1
Cell therapy for advanced kidney cancer

This trial tests a new cell therapy (HS-IT101) for people with advanced clear cell renal cell carcinoma, a type of kidney cancer that has spread. The treatment aims to boost the immune system to fight the cancer. Participants must be in good general health and have had no recent cancer treatments.

NCT05430373Recruiting· Phase 1
Injection study for advanced solid tumors using tumor-fighting cells

This Phase 1 trial tests GT101, an injection made from your own tumor-fighting immune cells, for advanced solid cancers that can’t be removed with surgery. It’s mainly aimed at checking safety and early signs of whether the treatment may work.

Beijing, Beijing Municipality
NCT04977453Recruiting· Phase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds

This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.

New York, New York
NCT07227415Recruiting· Phase 1/Phase 2
Study of a new drug for advanced kidney cancer

This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.

Phoenix, Arizona
NCT05615974Recruiting· Phase 1/Phase 2
LM-101 injection study for advanced solid tumors

This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.

Guangzhou, Guangdong

Hear when a new Adult trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.